Reporting of adverse events ONLY

Patients should always seek the advice of a doctor or pharmacist in case of adverse events.

If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:

00420 224 910 672

(from 09.00-17.30 CET)

00420 723 694 460

(non-stop 24/7)

To contact us about any other issue please call:

+420 22 491 0000or our regional offices.

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

00420 224 910 672

(09.00-17.30 CET)

00420 723 694 460

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

Pharmaceutical regulatory affairs specialist ELC Group establishes global HQ in Cambridge, UK

Cambridge, UK, February 8 2012 – ELC GROUP, the pan-European pharmaceutical regulatory affairs organisation, today formally announces that it has established its global headquarters in Cambridge, UK. The opening of the new global HQ follows a year of exceptional revenue growth for ELC Group, and strengthens ELC Group’s ability to serve customers across its major global regions. The Cambridge operation is being headed by Anna Szymanska, General Manager Regulatory Affairs.

Last year, ELC Group announced a doubling of its revenues for the first quarter of 2011, and the company has seen demand soar for its regulatory affairs consulting and commercialisation services across key global markets. Customer demand has been particularly strong for ELC Group’s pharmacovigilance solutions and regulatory submission services. ELC Group’s specialist services – delivered by highly-skilled teams of regulatory affairs professionals – have experienced exponential growth in strategic territories including India and China, leading to the establishment of a new operational headquarters for the high-growth organisation.

ELC GROUP has previously announced its intention to explore acquisition targets in the speciality CROs and services companies’ landscape, and will lead its continued market expansion from the newly-opened UK base. ELC Group is also exploring commercial opportunities in the South Asia market and is planning to implement expansion plans in the region over the coming months. To support ELC Group’s growth strategy, the new global headquarters will host a core team of senior regulatory affairs experts and business development personnel, with plans to recruit additional experienced regulatory affairs staff by the end of the year.

Marco Rubinstein, CEO of ELC Group, comments: “In tough market conditions, we have enjoyed a year of truly outstanding revenue growth. This really demonstrates the value our global customers are deriving from our core offering, and provides an excellent platform for the strategic plans we have in place to expand the breadth and depth of ELC Group’s capabilities.” He continues: “The establishment of our new global headquarters provides us with an optimal location from which to execute our growth ambitions and cement our leadership position in the regulatory affairs service market.”

ELC Group helps pharmaceutical clients expedite time-to-market through a broad range of development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialisation services. ELC Group delivers its customised solutions through four core business segments: Regulatory Affairs Services; Medical Devices; EU REACH (Registration, Evaluation and Authorisation of Chemicals) Regulation Services; and Corporate Languages Solutions (Translations, Design, DTP, Localisation).

NOTE: The statements made in this Press Release may contain forward-looking statements that involve a number of risks and uncertainties.